Free Trial

Opthea (OPT) Competitors

Opthea logo
$3.41 +0.23 (+7.23%)
As of 07/17/2025

OPT vs. BLTE, CNTA, VCEL, IRON, HRMY, IDYA, CGON, ARQT, SRPT, and OCUL

Should you be buying Opthea stock or one of its competitors? The main competitors of Opthea include Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), Disc Medicine (IRON), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), CG Oncology (CGON), Arcutis Biotherapeutics (ARQT), Sarepta Therapeutics (SRPT), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry.

Opthea vs. Its Competitors

Belite Bio (NASDAQ:BLTE) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Belite Bio had 2 more articles in the media than Opthea. MarketBeat recorded 2 mentions for Belite Bio and 0 mentions for Opthea. Opthea's average media sentiment score of 1.87 beat Belite Bio's score of 0.37 indicating that Opthea is being referred to more favorably in the news media.

Company Overall Sentiment
Belite Bio Neutral
Opthea Very Positive

Belite Bio has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500. Comparatively, Opthea has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.

Opthea's return on equity of 0.00% beat Belite Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Belite BioN/A -32.07% -30.91%
Opthea N/A N/A N/A

Belite Bio presently has a consensus target price of $96.67, indicating a potential upside of 58.68%. Opthea has a consensus target price of $1.33, indicating a potential downside of 60.90%. Given Belite Bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Belite Bio is more favorable than Opthea.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Belite Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Opthea
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.17

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 56.0% of Opthea shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 3.2% of Opthea shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Belite Bio has higher earnings, but lower revenue than Opthea.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Belite BioN/AN/A-$36.14M-$1.36-44.79
Opthea$120K4,373.61-$220.24MN/AN/A

Summary

Opthea beats Belite Bio on 7 of the 13 factors compared between the two stocks.

Get Opthea News Delivered to You Automatically

Sign up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OPT vs. The Competition

MetricOptheaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$524.84M$2.96B$5.54B$9.41B
Dividend YieldN/A2.46%3.75%4.03%
P/E RatioN/A8.2821.0120.09
Price / Sales4,373.61303.17433.8199.01
Price / CashN/A42.5936.1658.27
Price / Book-6.097.678.125.65
Net Income-$220.24M-$55.28M$3.25B$257.91M
7 Day PerformanceN/A2.50%0.97%2.09%
1 Month PerformanceN/A11.70%7.36%11.13%
1 Year Performance64.73%4.89%31.31%18.40%

Opthea Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OPT
Opthea
0.3999 of 5 stars
$3.41
+7.2%
$1.33
-60.9%
+64.7%$524.84M$120K0.008Gap Up
BLTE
Belite Bio
1.831 of 5 stars
$63.58
+0.6%
$96.67
+52.0%
+26.6%$2.02BN/A-46.7510High Trading Volume
CNTA
Centessa Pharmaceuticals
3.4077 of 5 stars
$15.13
+4.9%
$27.89
+84.3%
+67.6%$2.02B$15M-8.36200Positive News
High Trading Volume
VCEL
Vericel
3.6832 of 5 stars
$39.82
-0.3%
$61.14
+53.5%
-29.9%$2.00B$238.54M1,327.78300News Coverage
Positive News
IRON
Disc Medicine
3.0955 of 5 stars
$57.74
+1.5%
$96.70
+67.5%
+21.4%$2.00BN/A-14.7330News Coverage
Insider Trade
HRMY
Harmony Biosciences
4.801 of 5 stars
$34.71
+2.1%
$51.33
+47.9%
+10.1%$1.99B$714.73M13.25200Positive News
IDYA
IDEAYA Biosciences
3.5047 of 5 stars
$22.58
+0.4%
$47.55
+110.6%
-45.7%$1.98B$7M-6.2980Positive News
CGON
CG Oncology
2.531 of 5 stars
$25.90
-3.1%
$56.80
+119.3%
-25.5%$1.97B$1.14M-17.1561News Coverage
Analyst Forecast
ARQT
Arcutis Biotherapeutics
2.0428 of 5 stars
$15.90
+5.9%
$18.80
+18.2%
+50.7%$1.90B$196.54M-15.29150
SRPT
Sarepta Therapeutics
4.8279 of 5 stars
$19.23
+5.8%
$58.54
+204.4%
-85.0%$1.89B$2.23B-7.151,372Trending News
Analyst Forecast
Analyst Revision
Gap Down
Trading Halted
High Trading Volume
OCUL
Ocular Therapeutix
3.9265 of 5 stars
$11.27
+2.2%
$17.33
+53.8%
+42.3%$1.80B$63.72M-9.80230

Related Companies and Tools


This page (NASDAQ:OPT) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners